A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB)

Researchers develop a new technology for studying how brain tumours interact with the blood-brain barrier to inform future treatment strategies.

Researchers identify predictive immune ‘signatures’ in liver cancer patients that can help tailor and improve the success rates of combined immunotherapy and radiotherapy.

Researchers performed a comprehensive genetic sequencing of individual tumour cells to refine existing colorectal cancer classifications.

An experimental antibody therapy for solid tumours in adults also shows promise in improving quality of life for paediatric patients.

Researchers discover a protein-cutting enzyme that may be responsible for inflammatory skin conditions triggered by yeast species.

A polymer-based drug delivery innovation can replace invasive eye treatments for retinal diseases.

A programmable gene editing tool targets and eliminates a rapidly mutating RNA virus responsible for hand, foot and mouth disease.

Researchers reveal how disrupting a key genetic control mechanism can significantly hinder the progression and spread of an aggressive and difficult-to-treat form of breast cancer.

A*STAR researchers identified the mechanism behind how a common gene mutation in kidney cancer impacts chromatin remodelling and drives tumour development, opening up new possibilities for therapeutic interventions.

A*STAR scholar Phyllis Phuah aims to develop better treatments for metabolic diseases by understanding how gut microbes help (or hinder) the connections between our body and brain.

A new genetically-modified mouse model offers a powerful and reliable platform to study human immune responses to complex infections.

By studying the gut-brain axis, Hwei Ee Tan hopes to unravel how dietary intake and the gut microbiome play important roles in human health and behaviour.